-

04:37:18 PM

CYCN Stock News

CYCN - Cyclerion Therapeutics Inc

06/22/22 8:30 AM

Nasdaq : CYCN

clinical trial

Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Company to discuss positive topline and additional clinical data for CY6463 in MELAS patients Mitochondrial disease clinician-researcher, Amel Karaa, M.D., to discuss the potential future impact on patients Webcast scheduled for Tuesday, June 28 th from 8 – 9 a.m. EDT CAMBRIDGE, Mass., June 22,

RHEA-AI

neutral

06/17/22 8:00 AM

Nasdaq : CYCN

Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease

RHEA-AI

neutral

06/10/22 7:00 AM

Nasdaq : CYCN

clinical trial

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium

Data from an eight-patient, open-label study demonstrate improvements across multiple biomarkers of mitochondrial function, inflammation, cerebral blood flow, and functional connectivity CY6463 was well tolerated, with no reports of serious adverse events (SAEs) or treatment discontinuation due to

RHEA-AI

neutral

06/06/22 7:00 AM

Nasdaq : CYCN

conferencesclinical trial

Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage

RHEA-AI

neutral

05/04/22 4:01 PM

Nasdaq : CYCN

earnings

Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results

Characterizing the novel neuropharmacology of CY6463’s NO-sGC-cGMP signal modulation in an integrated clinical strategy currently involving three ongoing, exploratory, biomarker-rich, signal seeking studies: Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) study

RHEA-AI

neutral

02/24/22 4:01 PM

Nasdaq : CYCN

Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates

Phase 2a study in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) enrollment closed; topline data expected in Q2 2022 Phase 1b study in Cognitive Impairment Associated with Schizophrenia (CIAS) enrollment ongoing; topline data expected in H2 2022 Phase 2a study in

RHEA-AI

neutral

02/23/22 8:00 AM

Nasdaq : CYCN

Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and

RHEA-AI

positive

01/26/22 8:00 AM

Nasdaq : CYCN

clinical trial

Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease with Vascular Pathology

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive

RHEA-AI

neutral

11/11/21 5:32 PM

Nasdaq : CYCN

conferences

Cyclerion Therapeutics to Participate in Jefferies London Healthcare Conference

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that management will attend the Jefferies London Healthcare Conference on

RHEA-AI

neutral

11/09/21 4:01 PM

Nasdaq : CYCN

earnings

Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update

First patients enrolled in study in Cognitive Impairment Associated with Schizophrenia (CIAS) Patient screening underway in study in Alzheimer’s disease with vascular pathology (ADv) Enrollment ongoing in study in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS);

RHEA-AI

neutral

CYCN Data

Websitewww.cyclerion.com
Security nameCyclerion Therapeutics Inc
Issue typecs
Sic code2834
Employees51
Tags
- Pharmaceuticals: Major
- Health Technology

About Cyclerion Therapeutics Inc

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Cyclerion's lead program is CY6463, a novel, first-in-class, CNS-penetrant, sGC stimulator that modulates a key node in a fundamental CNS signaling network. The multidimensional pharmacology elicited by the stimulation of sGC has the potential to impact a broad range of CNS diseases. CY6463 has shown rapid improvement in biomarkers associated with cognitive impairment and is currently in clinical development for Alzheimer's Disease with Vascular pathology (ADv) and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS).